Drug Trial Radar · NCT07579741
A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 26, 2026
Primary completion
Feb 12, 2027
Study completion Sep 28, 2027
Sponsor
- Lead sponsor
- Jecho Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase Ib clinical trial is an add-on study based on combination antiretroviral therapy (cART). It adopts a multicenter, randomized, double-blind, placebo-controlled, multiple-dose design to evaluate the safety and efficacy of multiple intramuscular injections of JL18008 added to cART in HIV immunological non-responders (INRs). Based on the Phase Ia clinical data, three dose groups are planned for the Phase Ib trial: 20, 40, and 70 μg/kg of JL18008. Each group is planned to enroll 10 subjects (8 receiving active drug and 2 receiving placebo). All subjects must maintain their original cART regimen unchanged. Subjects in the active treatment groups will receive JL18008 injection in addition to cART, while those in the control group will receive placebo (JL18008 injection buffer) in addition to cART. The dosing regimen is tentatively once weekly (QW) for 4 consecutive weeks, which constitutes one treatment cycle, followed by an observation/follow-up period. The study drug will be administered by intramuscular injection.
Conditions
- HIV Infections
Interventions
JL18008 20 μg/kgDrug
Participants receive JL18008 20 μg/kg by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Placebo (for 20 μg/kg Group)Drug
Participants receive placebo (JL18008 injection buffer) by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
JL18008 40 μg/kgDrug
Participants receive JL18008 40 μg/kg by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Placebo (for 40 μg/kg Group)Drug
Participants receive placebo (JL18008 injection buffer) by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
JL18008 70 μg/kgDrug
Participants receive JL18008 70 μg/kg by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Placebo (for 70 μg/kg Group)Drug
Participants receive placebo (JL18008 injection buffer) by intramuscular injection once weekly for 4 weeks, in addition to their stable combination antiretroviral therapy (cART).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by DAIDS v2.1Time frame: Up to 24 weeks
- Change from Baseline in Vital Signs: Pulse Rate (bpm)Time frame: Up to 24 weeks
- Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (mmHg)Time frame: Up to 24 weeks
- Change from Baseline in Hematology ParametersTime frame: Up to 24 weeks
- Change from Baseline in Serum Chemistry ParametersTime frame: Up to 24 weeks
- Change from Baseline in Coagulation ParametersTime frame: Up to 24 weeks
- Change from Baseline in ECG Parameter: QTcF IntervalTime frame: Up to 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.